Chronic lymphocytic leukemia/small lymphocytic lymphoma

CLL and SLL involve the same kind of abnormal B lymphocyte. The name largely depends on where the cells are found: CLL has a characteristic number in blood, while SLL is mainly in lymph nodes or other tissues.

This cancer usually affects older adults and often develops slowly. Blood tests, examination and sometimes a tissue biopsy establish the diagnosis. Before treatment, testing such as TP53 analysis, chromosome studies and IGHV mutation status helps guide the choice of medicines.

CLL/SLL arises when B cells acquire changes that allow them to survive and accumulate. Its cause is often unknown. Risk can run in families, but most cases are not explained by a simple inherited gene change.

The abnormal cells do not provide normal immune protection. CLL/SLL is not contagious, and finding a chromosome or gene abnormality in the cancer does not itself show an inherited condition.

Some people feel well and discover CLL through a blood test. Others have swollen lymph nodes, fatigue, night sweats, weight loss or an enlarged spleen. Low blood counts can result from marrow involvement or immune destruction of blood cells.

Infection risk may increase even when treatment has not started. A small proportion of cases transform into a more aggressive lymphoma, often called Richter transformation. Rapidly changing symptoms or lymph-node growth need clinical reassessment rather than an assumption that this is ordinary CLL progression.

Asymptomatic disease that does not meet treatment criteria is often actively monitored. Starting treatment simply because CLL cells are present does not benefit everyone; the team watches symptoms, blood counts and the pace of change.

When treatment is needed, options include BTK inhibitors and venetoclax-based combinations, often with an anti-CD20 antibody. The choice and duration depend on disease genetics, previous treatment, other health conditions and patient preferences. CAR-T therapy and clinical trials are options for selected previously treated patients.

Allogeneic transplantation is uncommon and generally considered after resistance to important targeted-treatment classes or in selected aggressive transformation. It can produce durable disease control but carries substantial risks. Autologous transplantation is not standard treatment for CLL itself.

Active monitoring still means living with a diagnosis and attending follow-up. Some people want help understanding which changes matter and how often tests are planned. Treatment may be continuous or time-limited, depending on the regimen.

Infection prevention, vaccines appropriate to the person’s immune status and attention to other cancers are part of care. New fever or signs of infection should be discussed promptly with the treatment team. Drug-specific monitoring may include bleeding risk, heart rhythm, interactions or tumor lysis precautions.

Most people with CLL/SLL do not need a registry donor. A donor is relevant only if allogeneic transplantation is chosen for a particular clinical situation.

If it is chosen, the team assesses relatives, unrelated donors and appropriate alternative grafts. The usual autologous CAR-T products use a patient’s own modified T cells, so CAR-T treatment should not be described as receiving a registry donor’s marrow. Registry recruitment supports other patients too, regardless of which disease page brought a reader here.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?